FDA accepts a second generic tirzepatide application, from Amneal and Adalvo

The FDA has accepted a second application for generic tirzepatide, the drug sold as Mounjaro and Zepbound. Amneal Pharmaceuticals and its partner Adalvo announced on July 8, 2026 that the agency agreed to review two Abbreviated New Drug Applications, or ANDAs, covering a generic tirzepatide autoinjector ^[1]. That follows Sandoz's own acceptance on June 29, 2026, for two ANDAs covering both the diabetes and obesity indications ^[1]. Together, these are the first real generic filings for tirzepatide, even though a launch date is still nowhere in sight ^[1].

FDA acceptance is a procedural step, not an approval. It means the agency checked the paperwork and found it complete enough to review, nothing more ^[1]. The FDA's typical ANDA review runs about 10 months, though a first-cycle generic with an injector device could take longer, since the agency also has to check whether the device performs the same as Lilly's pen ^[1].

Even if the FDA eventually approves one of these applications, that does not clear a generic to reach pharmacy shelves. Eli Lilly holds a patent on the tirzepatide molecule itself that runs to roughly January 2036, plus separate device and formulation patents that patent trackers say could push exclusivity into 2039 or beyond ^[1]. A generic maker can only get around that wall through a Paragraph IV court challenge arguing the patent is invalid, or through a licensed early-entry deal with Lilly, similar to what happened with some generic insulins ^[1]. Neither path is quick or guaranteed, which is why realistic estimates put actual generic tirzepatide availability around 2036 to 2038 ^[1].

This is a different track from compounded tirzepatide, which some pharmacies made for individual patients without proving bioequivalence to the FDA. That option narrowed sharply after the FDA resolved the tirzepatide shortage in March 2025 and later moved to exclude tirzepatide from the list of substances compounders can use in bulk ^[1]. A generic, by contrast, is a fully FDA-regulated copy tested for bioequivalence and sold under the same regulatory system as the brand drug ^[1].

Why it matters for patients

For anyone paying for tirzepatide today, nothing changes. The same options that existed last week remain: Zepbound through Lilly's self-pay program at $299 to $449 a month depending on dose, Medicare Part D coverage at $50 a month through a Bridge program that started July 1, 2026, or a narrow compounded option for patients with a documented medical reason ^[1]. The generic filings are worth knowing about for long-term planning, but they do not affect a decision someone is making this month ^[1].

Patients budgeting around when tirzepatide might get cheaper through the generic system, rather than through an insurance or manufacturer program, are better served planning around the 2036 to 2038 window than around this month's FDA news ^[1]. The gap between an accepted application and an affordable pharmacy shelf price can run a decade or more when patents are involved.

What happens next

A few developments would move this timeline meaningfully. A Paragraph IV patent challenge from Sandoz or Amneal could open the door years earlier if a court ruled against Lilly's patents ^[1]. An FDA approval decision on either ANDA, expected sometime in 2027 under the standard 10-month review clock, would confirm the generics work technically, even though they still could not launch ^[1]. And any sign that Lilly is negotiating a licensed early-entry deal would be the clearest signal that a real launch date is moving closer ^[1]. None of that has happened yet.